Article info
PDFClinical and epidemiological research
Concise report
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
- Correspondence to Michael H Schiff, Rheumatology Department, University of Colorado, 5400 South Monaco, Englewood, Colorado CO 80111, USA; michael.schiff{at}me.com
Citation
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Publication history
- Received February 3, 2014
- Revised May 30, 2014
- Accepted June 1, 2014
- First published June 27, 2014.
Online issue publication
October 30, 2014
Article Versions
- Previous version (27 June 2014).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions